Analysis
Opening up data at the European Medicines Agency
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2686 (Published 10 May 2011) Cite this as: BMJ 2011;342:d2686
Related articles
- Editorial Published: 13 December 2007; BMJ 335 doi:10.1136/bmj.39400.376424.BE
- Paper Published: 29 May 2003; BMJ 326 doi:10.1136/bmj.326.7400.1171
- News Published: 25 November 2004; BMJ 329 doi:10.1136/bmj.329.7477.1253
- Research Published: 03 January 2012; BMJ 344 doi:10.1136/bmj.d7202
- Research Methods & Reporting Published: 03 January 2012; BMJ 344 doi:10.1136/bmj.d8013
- Analysis Published: 17 January 2012; BMJ 344 doi:10.1136/bmj.d7898
- Feature Published: 15 February 2012; BMJ 344 doi:10.1136/bmj.e976
- News Published: 23 February 2012; BMJ 344 doi:10.1136/bmj.e1360
- News Published: 28 March 2012; BMJ 344 doi:10.1136/bmj.e2388
- Editorial Published: 20 November 2012; BMJ 345 doi:10.1136/bmj.e7888
- Research Published: 20 November 2012; BMJ 345 doi:10.1136/bmj.e7570
- Analysis Published: 20 December 2012; BMJ 345 doi:10.1136/bmj.e8522
- Research Methods & Reporting Published: 09 January 2013; BMJ 346 doi:10.1136/bmj.e7586
- Research Published: 23 April 2013; BMJ 346 doi:10.1136/bmj.f2231
- Research Published: 04 June 2014; BMJ 348 doi:10.1136/bmj.g3510
- Letter Published: 05 July 2011; BMJ 343 doi:10.1136/bmj.d4203
- Letter Published: 15 May 2013; BMJ 346 doi:10.1136/bmj.f3001
- Analysis Published: 30 December 2014; BMJ 349 doi:10.1136/bmj.g6714
- News Published: 15 November 2016; BMJ 355 doi:10.1136/bmj.i6103
- News Published: 14 August 2018; BMJ 362 doi:10.1136/bmj.k3513
- Editorial Published: 19 January 2022; BMJ 376 doi:10.1136/bmj.o102
See more
- Cancer drugs remain FDA approved despite lack of benefit, study findsBMJ December 06, 2016, 355 i6568; DOI: https://doi.org/10.1136/bmj.i6568
- Johnson & Johnson is ordered to pay $1bn over faulty hip implantsBMJ December 06, 2016, 355 i6551; DOI: https://doi.org/10.1136/bmj.i6551
- Bill to boost medical research funding and speed drug approval passes US houseBMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498
- Trial of novel leukaemia drug is stopped for second time after two more deathsBMJ November 25, 2016, 355 i6376; DOI: https://doi.org/10.1136/bmj.i6376
- Promise of new Alzheimer’s drug is dashed after lack of evidenceBMJ November 24, 2016, 355 i6362; DOI: https://doi.org/10.1136/bmj.i6362
Cited by...
- Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols
- Institute for Scientific Freedom
- Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis
- EMA scales back transparency initiatives because of workload
- Redefining the 'E in EBM
- Secrecy or transparency? The future of regulatory trial data
- Risks of duloxetine for stress incontinence outweigh benefits, say researchers
- Drugs and Devices: Comparison of European and U.S. Approval Processes
- Evidence-informed recommendations to reduce dissemination bias in clinical research: conclusions from the OPEN (Overcome failure to Publish nEgative fiNdings) project based on an international consensus meeting
- "Human guinea pig" asks for animal studies
- Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications
- Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports
- The pioneers of transparency
- AbbVie considers harms to be commercially confidential information: sign a petition
- Roche continues to drag its feet on access to Tamiflu data
- Searching for unpublished data for Cochrane reviews: cross sectional study
- SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
- Deficiencies in proposed new EU regulation of clinical trials
- The new BMJ policy on sharing data from drug and device trials
- Sharing of clinical trial data among trialists: a cross sectional survey
- Guidelines for the practical stability studies of anticancer drugs: a European consensus conference
- Learning from Hackers: Open-Source Clinical Trials
- Strengthening and Opening Up Health Research by Sharing Our Raw Data
- Sunshine at the European regulator
- Rethinking credible evidence synthesis
- Out of sight but not out of mind: how to search for unpublished clinical trial evidence
- UK drug regulator destroys all evidence after 15 years
- EMA's response to articles
- Still waiting for functional EU Clinical Trials Register
- Proactive transparency?
- Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses